Impact of Resveratrol on Brain Function and Structure
Клучни зборови
Апстракт
Опис
Cell and animal studies postulated various beneficial effects of resveratrol, ranging from a reduction of inflammatory processes and the treatment of cancer to the prevention of cardiovascular diseases and stroke. With regard to cognitive decline, rodent models for Alzheimer's disease (AD) showed improved learning and decelerated hippocampal neurodegeneration after intake of resveratrol.
Animal and first human studies provided evidence that resveratrol might serve as an easy, cost-effective option to develop novel prevention and treatment strategies against age-associated cognitive decline. To test this hypothesis, the researchers study general brain structure and function on healthy older individuals (> 60years old).
Датуми
| Последен пат проверено: | 01/31/2017 |
| Прво доставено: | 11/05/2015 |
| Поднесено е проценето запишување: | 11/30/2015 |
| Прво објавено: | 12/02/2015 |
| Последното ажурирање е доставено: | 02/05/2017 |
| Последно ажурирање објавено: | 02/07/2017 |
| Крај на датумот на започнување на студијата: | 03/31/2016 |
| Проценет датум на примарно завршување: | 12/31/2016 |
| Проценет датум на завршување на студијата: | 12/31/2016 |
Состојба или болест
Интервенција / третман
Dietary Supplement: resveratrol supplementation
Dietary Supplement: placebo supplementation
Фаза
Групи за раце
| Рака | Интервенција / третман |
|---|---|
| Experimental: resveratrol supplementation Dietary Supplement: Resveratrol | Dietary Supplement: resveratrol supplementation 6 months of resveratrol supplementation |
| Placebo Comparator: placebo supplementation Dietary Supplement: Placebo | Dietary Supplement: placebo supplementation 6 months of placebo intake |
Критериуми за подобност
| Возраст подобни за студии | 60 Years До 60 Years |
| Полови квалификувани за студии | All |
| Прифаќа здрави волонтери | Да |
| Критериуми | Inclusion Criteria: - subjects who are healthy or with subjective memory complaints - older than 60 years old - normal to overweight participants (BMI: 22-40 kg/sqm) Exclusion Criteria: - dementia - Psychiatric diseases - severe untreated internal diseases - diabetes - younger than 60 years - BMI < 22 or >40 |
Исход
Мерки на примарниот исход
1. Change from baseline Verbal Learning Task Scores at 6 months [Baseline (timepoint 0), after 6 months (timepoint 6 months)]
Секундарни мерки на исходот
1. Change from baseline Verbal Learning Task Scores at 12 months [after 12 months (timepoint 12 months)]
2. Mini Mental State Examination [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
3. Structural changes on the brain MRI images [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
4. Functional changes on the brain MRI images [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
5. Plasma biomarkers [Baseline (timepoint 0), after 6 months (timepoint 6 months) and after 12 months (timepoint 12 months)]
